Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 99-106, January 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fong, T. A. T.
Right arrow Articles by McMahon, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fong, T. A. T.
Right arrow Articles by McMahon, G.
[Cancer Research 59, 99-106, January 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types

T. Annie T. Fong1, Laura K. Shawver, Li Sun, Cho Tang, Harald App, T. Jeff Powell, Young H. Kim, Randall Schreck, Xueyan Wang, Werner Risau, Axel Ullrich, K. Peter Hirth and Gerald McMahon2

SUGEN, Inc., South San Francisco, California 94080 [T. A. T. F., L. K. S., L. S., C. T., H. A., T. J. P., Y. H. K., R. S., X. W., K. P. H., G. M]; Max-Planck Institut fur Physiologische and Klinische Forschung, Bad Nauheim, Germany [W. R.]; and Max-Planck Institut fur Biochemie, Martinsried, Germany 82152 [A. U.]

SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of subcutaneous tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.




This article has been cited by other articles:


Home page
 IOVSHome page
D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen
Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1836 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti
Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion
Mol. Cancer Res., April 1, 2008; 6(4): 525 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Timke, H. Zieher, A. Roth, K. Hauser, K. E. Lipson, K. J. Weber, J. Debus, A. Abdollahi, and P. E. Huber
Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy
Clin. Cancer Res., April 1, 2008; 14(7): 2210 - 2219.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Takahashi, M. T. Itoh, and B. Ishizuka
Human Chorionic Gonadotropin Induces Nestin Expression in Endothelial Cells of the Ovary via Vascular Endothelial Growth Factor Signaling
Endocrinology, January 1, 2008; 149(1): 253 - 260.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Claes, P. Wesseling, J. Jeuken, C. Maass, A. Heerschap, and W. P.J. Leenders
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Mol. Cancer Ther., January 1, 2008; 7(1): 71 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study
Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
A. C. White, K. J. Lavine, and D. M. Ornitz
FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network
Development, October 15, 2007; 134(20): 3743 - 3752.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al.
Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
C. R. Amura, K. S. Brodsky, R. Groff, V. H. Gattone, N. F. Voelkel, and R. B. Doctor
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
Am J Physiol Cell Physiol, July 1, 2007; 293(1): C419 - C428.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan
Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells
Cancer Res., April 15, 2007; 67(8): 3683 - 3690.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. L. Warner-Schmidt and R. S. Duman
VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants
PNAS, March 13, 2007; 104(11): 4647 - 4652.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
J. D. Leslie, L. Ariza-McNaughton, A. L. Bermange, R. McAdow, S. L. Johnson, and J. Lewis
Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis
Development, March 1, 2007; 134(5): 839 - 844.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Nakazawa, H. Nagai, M. Shin, and G. Sheng
Negative regulation of primitive hematopoiesis by the FGF signaling pathway
Blood, November 15, 2006; 108(10): 3335 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gomez, M. Gonzalez-Izquierdo, R. C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer
Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model
Endocrinology, November 1, 2006; 147(11): 5400 - 5411.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. A. Murphy, S. Makonnen, W. Lassoued, M. D. Feldman, C. Carter, and W. M.F. Lee
Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006)
Am. J. Pathol., November 1, 2006; 169(5): 1875 - 1885.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. H. Sung, F. N. Ziyadeh, A. Wang, P. E. Pyagay, Y. S. Kanwar, and S. Chen
Blockade of Vascular Endothelial Growth Factor Signaling Ameliorates Diabetic Albuminuria in Mice
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3093 - 3104.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Crokart, P. Martinive, J. DeWever, V. Gregoire, O. Feron, and B. Gallez
Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy
Cancer Res., October 1, 2006; 66(19): 9698 - 9704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L668 - L676.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Murakami, S. Iwai, S. Hiratsuka, M. Yamauchi, K. Nakamura, Y. Iwakura, and M. Shibuya
Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages
Blood, September 15, 2006; 108(6): 1849 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Troiani, O. Lockerbie, M. Morrow, F. Ciardiello, and S. G. Eckhardt
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Mol. Cancer Ther., July 1, 2006; 5(7): 1883 - 1894.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
B. Donahower, S. S. McCullough, R. Kurten, L. W. Lamps, P. Simpson, J. A. Hinson, and L. P. James
Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G102 - G109.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Majka, K. Fox, B. McGuire, J. Crossno Jr., P. McGuire, and A. Izzo
Pleiotropic role of VEGF-A in regulating fetal pulmonary mesenchymal cell turnover
Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1183 - L1192.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. S. Dawson, D. C. Zawieja, M. H. Wu, and H. J. Granger
Signaling pathways mediating VEGF165-induced calcium transients and membrane depolarization in human endothelial cells
FASEB J, May 1, 2006; 20(7): 991 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
B. W. Parcells, A. K. Ikeda, T. Simms-Waldrip, T. B. Moore, and K. M. Sakamoto
FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia
Stem Cells, May 1, 2006; 24(5): 1174 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. D. Covassin, J. A. Villefranc, M. C. Kacergis, B. M. Weinstein, and N. D. Lawson
Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish
PNAS, April 25, 2006; 103(17): 6554 - 6559.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. O. D. Achcar, Y. Demura, P. R. Rai, L. Taraseviciene-Stewart, M. Kasper, N. F. Voelkel, and C. D. Cool
Loss of Caveolin and Heme Oxygenase Expression in Severe Pulmonary Hypertension
Chest, March 1, 2006; 129(3): 696 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Sakimoto, K. Ohta, T. Yamazaki, S. Ohtani, H. Sahara, F. Sugawara, K. Sakaguchi, and M. Miura
{alpha}-Sulfoquinovosylmonoacylglycerol Is a Novel Potent Radiosensitizer Targeting Tumor Angiogenesis
Cancer Res., February 15, 2006; 66(4): 2287 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Sun, S. Stevanovic, M. Song, A. Schwantes, C. J. Kirkpatrick, D. Schadendorf, and K. Cichutek
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes
Blood, February 15, 2006; 107(4): 1476 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
P. M. Hoff, R. A. Wolff, K. Bogaard, S. Waldrum, and J. L. Abbruzzese
A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma
Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 100 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al.
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M.W. Laschke, A. Elitzsch, B. Vollmar, P. Vajkoczy, and M.D. Menger
Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions
Hum. Reprod., January 1, 2006; 21(1): 262 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. D. Miller, M. Miller, S. Mehrotra, B. Agarwal, B. H. Mock, Q.-H. Zheng, S. Badve, G. D. Hutchins, and G. W. Sledge Jr.
A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171
Clin. Cancer Res., January 1, 2006; 12(1): 281 - 288.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 971 - 979.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S.-W. Jin, D. Beis, T. Mitchell, J.-N. Chen, and D. Y. R. Stainier
Cellular and molecular analyses of vascular tube and lumen formation in zebrafish
Development, December 1, 2005; 132(23): 5199 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al.
ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. G. Bagley, W. Weber, C. Rouleau, and B. A. Teicher
Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy
Cancer Res., November 1, 2005; 65(21): 9741 - 9750.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Dowlati, K. Robertson, T. Radivoyevitch, J. Waas, N. P. Ziats, P. Hartman, F. W. Abdul-Karim, J. K. Wasman, J. Jesberger, J. Lewin, et al.
Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
Clin. Cancer Res., November 1, 2005; 11(21): 7938 - 7944.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
Z. Kan, S. Phongkitkarun, S. Kobayashi, Y. Tang, L. M. Ellis, T. Y. Lee, and C. Charnsangavej
Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model
Radiology, October 1, 2005; 237(1): 151 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
C. D. Kamat, D. E. Green, S. Curilla, L. Warnke, J. W. Hamilton, S. Sturup, C. Clark, and M. A. Ihnat
Role of HIF Signaling on Tumorigenesis in Response to Chronic Low-Dose Arsenic Administration
Toxicol. Sci., August 1, 2005; 86(2): 248 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Ma, G. Francia, A. Viloria-Petit, D. J. Hicklin, J. du Manoir, J. Rak, and R. S. Kerbel
In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy
Cancer Res., June 15, 2005; 65(12): 5365 - 5373.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. A. McGrath-Morrow, C. Cho, C. Cho, L. Zhen, D. J. Hicklin, and R. M. Tuder
Vascular Endothelial Growth Factor Receptor 2 Blockade Disrupts Postnatal Lung Development
Am. J. Respir. Cell Mol. Biol., May 1, 2005; 32(5): 420 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X.-F. Zhu, B.-F. Xie, J.-M. Zhou, G.-K. Feng, Z.-C. Liu, X.-Y. Wei, F.-X. Zhang, M.-F. Liu, and Y.-X. Zeng
Blockade of Vascular Endothelial Growth Factor Receptor Signal Pathway and Antitumor Activity of ON-III (2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a Component from Chinese Herbal Medicine
Mol. Pharmacol., May 1, 2005; 67(5): 1444 - 1450.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. Voelkel and L. Taraseviciene-Stewart
Emphysema: An Autoimmune Vascular Disease?
Proceedings of the ATS, April 1, 2005; 2(1): 23 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
K Gupta and J Zhang
Angiogenesis: a curse or cure?
Postgrad. Med. J., April 1, 2005; 81(954): 236 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Dalal, A. M. Berry, C. J. Cullinane, D. C. Mangham, R. Grimer, I. J. Lewis, C. Johnston, V. Laurence, and S. A. Burchill
Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family
Clin. Cancer Res., March 15, 2005; 11(6): 2364 - 2378.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Murga, O. Fernandez-Capetillo, and G. Tosato
Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2
Blood, March 1, 2005; 105(5): 1992 - 1999.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. G. Roberts, P. M. Whalen, E. Soderstrom, G. Moraski, J. P. Lyssikatos, H.-F. Wang, B. Cooper, D. A. Baker, D. Savage, D. Dalvie, et al.
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Cancer Res., February 1, 2005; 65(3): 957 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al.
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Hiratsuka, Y. Kataoka, K. Nakao, K. Nakamura, S. Morikawa, S. Tanaka, M. Katsuki, Y. Maru, and M. Shibuya
Vascular Endothelial Growth Factor A (VEGF-A) Is Involved in Guidance of VEGF Receptor-Positive Cells to the Anterior Portion of Early Embryos
Mol. Cell. Biol., January 1, 2005; 25(1): 355 - 363.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Dikov, J. E. Ohm, N. Ray, E. E. Tchekneva, J. Burlison, D. Moghanaki, S. Nadaf, and D. P. Carbone
Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation
J. Immunol., January 1, 2005; 174(1): 215 - 222.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood, January 1, 2005; 105(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge
ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity
Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. E. Hamden, P. W. Ford, A. G. Whitman, O. F. Dyson, S.-Y. Cheng, J. A. McCubrey, and S. M. Akula
Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection
J. Virol., December 1, 2004; 78(23): 13381 - 13390.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
Endocr. Rev., December 1, 2004; 25(6): 971 - 1010.
[Abstract] [Full Text] [PDF]

Home page